{"nctId":"NCT01707290","briefTitle":"Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation","startDateStruct":{"date":"2013-02"},"conditions":["Cystic Fibrosis"],"count":125,"armGroups":[{"label":"Ivacaftor","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor"]},{"label":"Observational","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants from Study 110 or Study 111 entering the ivacaftor arm must have completed the assigned study drug treatment duration in the previous study.\n* Participants from Study 113 entering the ivacaftor arm must have completed all study related treatments through the Follow-up Visit and met the Study 113 responder criteria during the previous study.\n* Participants entering the observational arm must have completed at least 4 weeks of study drug treatment in their previous study (Study 110 or Study 111), must have completed the previous study but do not wish to enroll in the ivacaftor arm, or must have completed the previous study but do not meet the inclusion criteria of the ivacaftor arm.\n* Participants of childbearing potential entering the ivacaftor arm must not be pregnant.\n* Participants entering the ivacaftor arm must be willing to comply with contraception requirements.\n\nExclusion Criteria (Ivacaftor Arm Only):\n\n* History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the Participant.\n* Use of moderate or strong inhibitors or inducers of cytochrome P450 (CYP) 3A.\n* Evidence of cataract or lens opacity at or before the Day 1 Visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm","description":"AE: any untoward medical occurrence in a participants during the studyÍ¾ the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs were defined as adverse events with start date or increased severity on and after the first dose of study drug through Week 108.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96, and 104","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 6 to 17 years and for female participants aged 6 to 15 years. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":"20.4"},{"groupId":"OG001","value":"78.3","spread":"21.1"},{"groupId":"OG002","value":"62.8","spread":"22.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"8"},{"groupId":"OG001","value":"4.4","spread":"7.7"},{"groupId":"OG002","value":"4","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"8.9"},{"groupId":"OG001","value":"5.5","spread":"8.3"},{"groupId":"OG002","value":"4.9","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"8.4"},{"groupId":"OG001","value":"7.1","spread":"8.3"},{"groupId":"OG002","value":"4.6","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"7.1"},{"groupId":"OG001","value":"7.5","spread":"8.2"},{"groupId":"OG002","value":"4.9","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"7.5"},{"groupId":"OG001","value":"6.4","spread":"10.7"},{"groupId":"OG002","value":"4.9","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"8.4"},{"groupId":"OG001","value":"8.2","spread":"8.3"},{"groupId":"OG002","value":"4.5","spread":"8.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"8.9"},{"groupId":"OG001","value":"7.8","spread":"9.2"},{"groupId":"OG002","value":"5.9","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"13.5"},{"groupId":"OG001","value":"7.7","spread":"7.6"},{"groupId":"OG002","value":"4.8","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"14.6"},{"groupId":"OG001","value":"9.9","spread":"6.4"},{"groupId":"OG002","value":"5.9","spread":"8.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"13.2"},{"groupId":"OG001","value":"4.9","spread":"5.8"},{"groupId":"OG002","value":"6.3","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Body Mass Index (BMI) at Week 2,12, 24, 36, 48, 60, 72, 84, 96 and 104","description":"BMI was defined as weight in kg divided by height in m\\^2. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.75","spread":"5.63"},{"groupId":"OG001","value":"23.15","spread":"5.28"},{"groupId":"OG002","value":"24.81","spread":"5.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.43"},{"groupId":"OG001","value":"0.16","spread":"0.47"},{"groupId":"OG002","value":"0.07","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.59"},{"groupId":"OG001","value":"0.39","spread":"0.62"},{"groupId":"OG002","value":"0.22","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.92"},{"groupId":"OG001","value":"0.65","spread":"0.96"},{"groupId":"OG002","value":"0.17","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"1.04"},{"groupId":"OG001","value":"0.64","spread":"1.07"},{"groupId":"OG002","value":"0.02","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"1.39"},{"groupId":"OG001","value":"0.58","spread":"1.22"},{"groupId":"OG002","value":"0.28","spread":"1.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"1.32"},{"groupId":"OG001","value":"0.25","spread":"1.09"},{"groupId":"OG002","value":"0.38","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"1.73"},{"groupId":"OG001","value":"0.45","spread":"1.34"},{"groupId":"OG002","value":"0.22","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"1.51"},{"groupId":"OG001","value":"0.33","spread":"1.42"},{"groupId":"OG002","value":"0.23","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"1.44"},{"groupId":"OG001","value":"0.1","spread":"1.49"},{"groupId":"OG002","value":"0.52","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"1.49"},{"groupId":"OG001","value":"0.16","spread":"1.37"},{"groupId":"OG002","value":"0.88","spread":"1.39"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Sweat Chloride at Week 2, 24, 48 and 104","description":"Sweat samples were collected using an approved collection device. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":"19.4"},{"groupId":"OG001","value":"80.2","spread":"22.8"},{"groupId":"OG002","value":"55.7","spread":"22.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.3","spread":"10.7"},{"groupId":"OG001","value":"-38.4","spread":"27.5"},{"groupId":"OG002","value":"-4.5","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13","spread":"18.4"},{"groupId":"OG001","value":"-39.2","spread":"27"},{"groupId":"OG002","value":"1.1","spread":"15.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"16.2"},{"groupId":"OG001","value":"-40.6","spread":"26.1"},{"groupId":"OG002","value":"-1.9","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.7","spread":"22.9"},{"groupId":"OG001","value":"-32.9","spread":"26.8"},{"groupId":"OG002","value":"5.4","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104","description":"The CFQ-R is a validated participant reported outcome measuring health related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health related quality of life. Baseline was defined as the most recent measurement before intake of the first dose of study drug (ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":"21.6"},{"groupId":"OG001","value":"72.4","spread":"20.3"},{"groupId":"OG002","value":"65.9","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"17.9"},{"groupId":"OG001","value":"4.5","spread":"17.5"},{"groupId":"OG002","value":"13.2","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"18"},{"groupId":"OG001","value":"5.7","spread":"18.5"},{"groupId":"OG002","value":"13.5","spread":"20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"19"},{"groupId":"OG001","value":"3.4","spread":"18.7"},{"groupId":"OG002","value":"8.5","spread":"14.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"19.3"},{"groupId":"OG001","value":"5.7","spread":"13.8"},{"groupId":"OG002","value":"7.9","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"17.6"},{"groupId":"OG001","value":"4.4","spread":"13.2"},{"groupId":"OG002","value":"11.4","spread":"15.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"18.6"},{"groupId":"OG001","value":"4.4","spread":"10.9"},{"groupId":"OG002","value":"8.6","spread":"19.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"22.2"},{"groupId":"OG001","value":"5.6","spread":"11.8"},{"groupId":"OG002","value":"8.6","spread":"19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"19.5"},{"groupId":"OG001","value":"8.8","spread":"14.1"},{"groupId":"OG002","value":"4.9","spread":"14.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"21.1"},{"groupId":"OG001","value":"0","spread":"9.5"},{"groupId":"OG002","value":"9.4","spread":"14.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"14"},{"groupId":"OG001","value":"1.9","spread":"8.8"},{"groupId":"OG002","value":"19.9","spread":"16"}]}]}]},{"type":"SECONDARY","title":"Number of Pulmonary Exacerbations Events","description":"Pulmonary exacerbation events include those events which require treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) in Observational Arm","description":"SAE was defined as a medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":121},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Cough","Headache","Sinus congestion","Sputum increased"]}}}